| CPC C07D 239/38 (2013.01) [A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61P 17/04 (2018.01); C07D 239/34 (2013.01); C07D 239/40 (2013.01); C07D 239/56 (2013.01); C07D 239/42 (2013.01)] | 8 Claims |
|
1. A compound represented by Formula 1 below, an optical isomer thereof or a pharmaceutically acceptable salt thereof:
![]() wherein,
L is single bond or straight or branched C1-C6 alkylene;
R1 is hydrogen; C3-C8 cycloalkyl; substituted or unsubstituted C6-C12 aryl, wherein the substituted C6-C12 aryl is substituted with one or more substituents selected from the group consisting of halogen, —NH2, straight or branched C1-C3 alkyl, and straight or branched C1-C3 alkoxy; substituted or unsubstituted heteroaryl consisting of 6 to 12 atoms containing one or more heteroatoms selected from the group consisting of N and O, wherein the substituted heteroaryl consisting of 6 to 12 atoms is substituted with one or more halogens; or heterocycloalkyl consisting of 6 to 10 atoms containing one or more heteroatoms selected from the group consisting of N and O; and
R2 is hydrogen or straight or branched C1-C3 alkyl;
R3 is substituted or unsubstituted C6-C10 aryl, wherein the substituted C6-C10 aryl is substituted with one or more methoxy groups; or substituted or unsubstituted morpholinyl or piperazinyl, wherein the substituted morpholinyl or piperazinyl is substituted with one or more hydroxyl ethyl groups; and
R4 is C1-C3 haloalkyl,
or
wherein,
L is single bond;
R1 is C3-C8 cycloalkyl; substituted or unsubstituted C6-C12 aryl, wherein the substituted C6-C12 aryl is substituted with one or more substituents selected from the group consisting of halogen, —NH2, straight or branched C1-C3 alkyl, and straight or branched C1-C3 alkoxy; substituted or unsubstituted heteroaryl consisting of 6 to 12 atoms containing one or more heteroatoms selected from the group consisting of N and O, wherein the substituted heteroaryl consisting of 6 to 12 atoms is substituted with one or more halogens; or heterocycloalkyl consisting of 6 to 10 atoms containing one or more heteroatoms selected from the group consisting of N and O; and
R2 is hydrogen or straight or branched C1C3 alkyl;
R3 is substituted C6-C10 aryl, wherein the substituted C6-C10 aryl is substituted with one or more methoxy groups; or substituted or unsubstituted morpholinyl or piperazinyl, wherein the substituted morpholinyl or piperazinyl is substituted with one or more hydroxyl ethyl groups; and
R4 is —SR5 or SO2R5, wherein R5 is straight or branched C1-C6 alkyl,
or
wherein,
L is straight or branched C1-C6 alkylene;
R1 is substituted or unsubstituted C6-C12 aryl, wherein the substituted C6-C12 aryl is substituted with one or more substituents selected from the group consisting of halogen, —NH2, straight or branched C1-C3 alkyl, and straight or branched C1-C3 alkoxy; substituted or unsubstituted heteroaryl consisting of 6 to 12 atoms containing one or more heteroatoms selected from the group consisting of N and O, wherein the substituted heteroaryl consisting of 6 to 12 atoms is substituted with one or more halogens; or heterocycloalkyl consisting of 6 to 10 atoms containing one or more heteroatoms selected from the group consisting of N and O; and
R2 is hydrogen or straight or branched C1-C3 alkyl;
R3 is substituted or unsubstituted morpholinyl or piperazinyl, wherein the substituted morpholinyl or piperazinyl is substituted with one or more hydroxyl ethyl groups; and
R4 is —SR5 or SO2R5, wherein R5 is straight or branched C1-C6 alkyl.
|